Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
OBJECTIVE
The plasma profile of a single dose of isosorbide mononitrate 25 mg (Elantan LA25) in healthy volunteers and in angina patients was examined.


METHODS
In volunteers and patients, blood samples for pharmacokinetics were obtained pre-dosing and at intervals for 24 h after dosing.


RESULTS
This formulation exhibited rapid absorption and plasma levels were maintained at > 100 ng ml-1 for up to 9 to 12 h.


CONCLUSIONS
A comparison of the pharmacokinetics of Elantan LA25 in volunteers and patients indicates that the profiles are similar.
Baxter
T
T
Schwarz Pharma Ltd, Chesham, UK.
Eadie
C J
CJ
D000328:Adult; D000787:Angina Pectoris / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate